öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºËïÐ㻪
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º193

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºµÚ¶þÁÙ´²Ñ§Ôº
Ö°³Æ£º
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÖ×Áöѧ
Ñо¿ÁìÓò£º ÁÜ°ÍÁö¼°Í·¾±²¿Ö×ÁöµÄÄÚ¿ÆÖÎÁÆ£»ÁÜ°ÍÁöµÄCAR-TÖÎÁÆ£»Ö×Áö·Ö×Ó°ÐÏòÖÎÁÆ
Ñо¿ÁìÓò£º ÁÜ°ÍÁö¼°Í·¾±²¿Ö×ÁöµÄÄÚ¿ÆÖÎÁÆ£»ÁÜ°ÍÁöµÄCAR-TÖÎÁÆ£»Ö×Áö·Ö×Ó°ÐÏòÖÎÁÆ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**£»**
µç×ÓÓʼþ£º **@vip.sina.com


¸öÈ˼òÊö :
ËïÐ㻪£¬Å®£¬Ö÷ÈÎҽʦ£¬½ÌÊÚ£¬Ö×ÁöѧѧÊõѧλ¼°öλÔÓéÀֵǼÈë¿ÚÏÂÔØѧλ˶ʿÑо¿Éúµ¼Ê¦¡£ÏÖÈδóÁ¬Ò½¿Æ´óѧ¸½ÊôµÚ¶þÒ½ÔºÖ×ÁöÄÚ¿ÆÁÜ°ÍÁö¼°Í·¾±²¿×¨¿Æ¸±Ö÷ÈΣ¨Ö÷³Ö¹¤×÷£©£¬Ö×ÁöÄڿƵ³Ö§²¿Êé¼Ç£¬ÄÚ¿Æ×Ü֧ίԱ¡£1970ÄêÉúÓÚÁÉÄþ³¯Ñô£¬1988Äê¾Í¶ÁÓÚ´óÁ¬Ò½¿Æ´óѧÁÙ´²Ò½ÁÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬1993Äê±ÏÒµÓÚ´óÁ¬Ò½¿Æ´óѧ£¬»ñѧʿѧ룬2002ÄêÓÚ´óÁ¬Ò½¿Æ´óѧ»ñÖ×Áöѧ˶ʿѧλ¡£2005ÄêƸΪ´óÁ¬Ò½¿Æ´óѧѧÊõÐÍ˶ʿÑо¿Éúµ¼Ê¦¡£2005ÄêÓÚÖйúҽѧ¿ÆѧԺÖ×ÁöÒ½ÔºÁÜ°ÍÁö²¡·¿½øÐÞ¡£2014ÄêÓÚÃÀ¹úµÂ¿ËÈø˹ÖÝMD°²µÂÉ­°©Ö¢ÕïÁÆÖÐÐÄÁÜ°ÍÁö¶à·¢¹ÇËèÁöÁÙ´²×ª»¯Ò½Ñ§Ñо¿ÊµÑéÊÒ¼°ÁÜ°ÍÁöÃÅÕï½øÐÞ£¬×ö·ÃÎÊѧÕß¡£Éç»á¼æÖ°£ºÖйúÀÏÄêѧѧ»áÀÏÄêÖ×ÁööλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áÁÜ°ÍÁöѪҺÖ×Áö·Öί»áÖ´ÐÐίԱ»áίԱ£»ÖйúÉúÎ﹤³Ìѧ»áÖ×Áö·Ö×Ó°ÐÏòÖÎÁÆ·Ö»áίԱ£»ÊÀ½çÖÐÁª°©Ö¢¹ÃÏ¢ÖÎÁÆÑо¿öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áµÚÒ»½ìÀíÊ»᳣ÎñÀíÊ£»ÁÉÄþÊ¡¿¹°©Ð­»áÁÜ°ÍÁööλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ÈÎίԱ£»ÁÉÄþÊ¡¿¹°©Ð­»á»¯ÁÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£»ÃÀ¹úÁÙ´²Ö×Áöѧѧ»á»áÔ±£¨ASCO»áÔ±£©£»ÖлªÒ½Ñ§ÉúÎïÃâÒßѧ»áίԱ£¬ÖлªÒ½Ñ§ÉúÎïÃâÒßѧ»áÖ×Áö·Ö»áίԱ¼°ÀíÊ¡£ÖлªÁÙ´²Ò½Ê¦ÔÓÖ¾ ÌØÔ¼±à¼­£»Up to dateÉó¸åר¼Ò£»ÖйúÖ×ÁöÁÙ´²Äê¼øÌØÔ¼±àί¡£CSCO»áÔ±£»ÖлªÒ½Ñ§»á»áÔ±¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿£º
2015ÄêÁ¢Ïî´óÁ¬Êйú¼ÊºÏ×÷ÏîÄ¿Ò»Ï±¾ÈËΪÏîÄ¿Ö÷³ÖÈË¡£ÏîÄ¿±àºÅ£º2015F11GH096 ¡£ÏîÄ¿Ãû³Æ£ºÖÎÁÆÄÑÖÎÐÔDLBCL°ÐÏòCD20µÄCAR-TµÄÑз¢ ÏîÄ¿Æðʼʱ¼ä£º2015.12.03-2017.12.02¿ÆÑо­·Ñ£º10ÍòÔª
´ú±íÎÄÕÂ
[1]. YUXUAN CHE,XING REN,LIYE XU,XIAOLEI DING,XUAN ZHANG,XIUHUA SUN*.Critical involvement of the ¦Á(1,2)-fucosyltransferase in multidrug resistance of human chronic myeloid leukemia.oncology reports,2016(35):3025-3033 IF 2.301
[2] ¶¡ÏþÀÙ,³Ì¾´¾´,ÕÅÏÒ,ÐìÀöÒ¶,ËïÐ㻪(ͨѶ×÷Õß).76Àý·Ç»ôÆæ½ðÁÜ°ÍÁö»¼ÕßËÀÍöÔ­Òò¼°Ó°ÏìÒòËØ·ÖÎö.ÖлªÀÏÄê¶àÆ÷¹Ù¼²²¡ÔÓÖ¾,2015,14(11):813-816
[3] ¶¡ÏþÀÙ,ÕÅÀÚ,ÕÅÏÒ,ÐìÀöÒ¶,ËïÐ㻪(ͨѶ×÷Õß).Ì×ϸ°ûÁÜ°ÍÁö18ÀýµÄÔ¤ºóÏà¹ØÒòËØ·ÖÎö. ÖлªÀÏÄê¶àÆ÷¹Ù¼²²¡ÔÓÖ¾,2015,14(11):825-828
[4] ºÎºì÷,³ÌêÊ, ËïÐ㻪(ͨѶ×÷Õß)£¬ÕÅÏÒ,ÐìÀöÒ¶,¶¡ÏþÀÙ.ÍâÖÜTϸ°ûÁÜ°ÍÁö»¼Õß65ÀýÔ¤ºóµÄÏà¹ØÒòËØ·ÖÎö. ÖлªÀÏÄê¶àÆ÷¹Ù¼²²¡ÔÓÖ¾,2015,14(10):770-774
[5] Yuxuan Che, Meixiang Zhou, Peng Zhan, Tiantian Zou, Xiuhua Sun(Corresponding Author). The anti-cancer effect of Huaier aqueous extract with rh-Endostatin and DDP*. The Chinese-German Journal of Clinical Oncology,2014,13(8) :349-354.
[6] Yuxuan Che,Jiawei Xu,Shuang Su,Xiuhua Sun(Corresponding Author), Man Li,Yang Zhang. Reversal effect of recombinant human Endostatin on cisplatin resistance in A549/DDP human lung adenocarcinoma cells in vitro.The Chinese-German Journal of Clinical Oncology,2013,12(11) :509-515.
[7] Jianing Jiang, Cong Liu,Kun Deng,Jinbo Zhao,Man Li,Jinghua Sun,Li Li,Liying Ban,Xiuhua Sun (Corresponding Author). The short-term efficacy of icotinib on the treatment of advanced non-small-cell lung cancer. The Chinese-German Journal of Clinical Oncology, 2014,13(1):1-5
[8].Xiuhua Sun,Yang Zhang,Xian Zhang,Jing Yu,Yinghua Li,Xiaoyan Yang,Zhaoxia Dai,Man Li.The clinical evaluation of Iressa first-line treatment of senium advanced-stage non-small cell lung cancer.Chinese-German Journal of Clinical Oncology,2008,7(4):203-206..
[9].Ëï溻ª,ËïÐ㻪£¨Í¨Ñ¶×÷Õߣ©°£¿ËÌæÄáÖÎÁÆÍíÆÚNSCLCµÄµäÐͲ¡Àý·ÖÎö.ÖйúÖ×ÁöÁÙ´²,2012, 39 (12): 868-870.
[10]..Ëï溻ª,ËïÐ㻪£¨Í¨Ñ¶×÷Õߣ©.°£¿ËÌæÄáÖÎÁÆ17ÀýÍíÆÚ·ÎÏÙ°©·ÇÎüÑÌ»¼ÕßµÄÔçÆÚÁÙ´²ÁÆЧ¹Û²ì.ÖйúÐÂÒ©ÔÓÖ¾,2012,21(14):1651-1653.